← back to search

Pamela F. Schwartz

Pfizer (United States) · US
Area of research
Pulmonary and Respiratory Medicine · Physiology
Research interest
Research interests include Inhalation and Respiratory Drug Delivery, Asthma and respiratory diseases, Veterinary Medicine and Surgery, and Chronic Obstructive Pulmonary Disease (COPD) Research.
h-index
17
citations
1,844
works
40
NIH funding
—
primary concept
—
email
✉ Find email ↗

Recent publications

AAV mini-dystrophin gene therapy for Duchenne muscular dystrophy: a phase 1b trial
Nature Medicine 2025cited by 14position: middledoi
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
New England Journal of Medicine 2017cited by 628position: middledoi
Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab
New England Journal of Medicine 2017cited by 362position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Steven E. Nissen · Cleveland Clinic1 papers (2017–2017)David Lévy · University of Chicago1 papers (2025–2025)— · 1 papers (2025–2025)J. Wouter Jukema · University of Palermo1 papers (2017–2017)Kelly A. Ryan · University of Michigan–Ann Arbor1 papers (2025–2025)William Duggan · Houston Methodist1 papers (2017–2017)Pierre Amarenco · Université Claude Bernard Lyon 11 papers (2017–2017)— · 1 papers (2025–2025)Wolfgang Köenig · Zimmer Biomet (United States)1 papers (2017–2017)— · 1 papers (2025–2025)Huihua Li · Dalian Medical University1 papers (2025–2025)Albert M. Kim · International Neuromodulation Society1 papers (2017–2017)James H. Revkin · AstraZeneca (Spain)1 papers (2017–2017)Jean‐Claude Tardif · United States Nuclear Regulatory Commission1 papers (2017–2017)Charles L. Shear · Macula Vision Research Foundation1 papers (2017–2017)Raúl D. Santos · Universidade de São Paulo1 papers (2017–2017)Russell J. Butterfield · University of Utah1 papers (2025–2025)Edward C. Smith · KU Leuven1 papers (2025–2025)Beth A. Belluscio · National Institute of Neurological Disorders and Stroke1 papers (2025–2025)John J.P. Kastelein · QRx Pharma (United States)1 papers (2017–2017)